Macrogenics
Clinical trials sponsored by Macrogenics, explained in plain language.
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase study tested a new combination of two drugs (vobramitamab duocarmazine and lorigerlimab) in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants received the d…
Phase: PHASE1 • Sponsor: MacroGenics • Aim: Disease control
Last updated May 01, 2026 17:42 UTC
-
New drug combo shows promise in slowing tough prostate cancer
Disease control CompletedThis study tested whether adding the experimental drug lorigerlimab to standard chemotherapy (docetaxel) can delay cancer growth in men with metastatic castration-resistant prostate cancer (mCRPC), a hard-to-treat form of the disease. About 154 participants were randomly assigned…
Phase: PHASE2 • Sponsor: MacroGenics • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC